Skip to content

Prostate Cancer Biomarker Tests Compared, and What Blood and Urine Tests Actually Tell Us

An elevated PSA result does not automatically mean prostate cancer. A reassuring blood or urine test does not completely rule it out, either.

PSA, PHI, 4Kscore and newer urine tests help estimate risk and guide decisions about further evaluation. They answer different questions, apply to different patient groups and cannot replace the tissue examination normally needed to confirm prostate cancer.

The important question is what happens after the result. Your clinician should explain what it means in your circumstances, whether additional testing is appropriate and what follow-up is planned.

When cancer is diagnosed later, that sequence also matters in a possible prostate cancer malpractice claim. A review must examine whether appropriate evaluation was missed and whether that failure caused additional harm.

Should Your Cancer Have Been Found Sooner?

Contact us today for a free consultation.

What a PSA Test Actually Measures

Prostate-specific antigen, or PSA, is a protein produced by both normal and cancerous prostate cells. The blood test measures its concentration, usually reported in nanograms per milliliter, or ng/mL.

Cancer can raise PSA, but so can benign prostatic hyperplasia, which is noncancerous prostate enlargement, and prostatitis, which is inflammation of the prostate.

The National Cancer Institute’s explanation of PSA testing emphasizes that there is no single number that reliably separates cancer from noncancerous conditions. A result below a laboratory’s cutoff cannot guarantee that cancer is absent. A result above it cannot establish that cancer is present. NCI

Interpretation involves more than comparing one result with a reference range. Your clinician may consider previous results, age, prostate size, examination findings, family history and medications.

Temporary Changes Can Affect the Result

Recent ejaculation, certain prostate procedures and urinary infections can affect PSA. The circumstances surrounding the blood draw can therefore influence whether a repeat measurement is useful.

The American Cancer Society’s guide to factors affecting PSA explains why clinicians ask about these issues before interpreting an abnormal result.

Repeating a newly elevated PSA can be a reasonable part of evaluation. It should come with an explanation and a follow-up plan, rather than an assumption that the elevation must have a harmless cause.

Finasteride and Dutasteride Can Lower PSA

Finasteride and dutasteride can suppress PSA, making medication history particularly important.

The prescribing information for finasteride reports that the medication reduces PSA by approximately 50% within six months. It also warns that a confirmed increase from the lowest value during treatment warrants evaluation, even when the result remains within the usual range for someone not taking the medication.

Your clinician needs to account for the medication, treatment duration and previous results. Do not stop medication or try to interpret the result using an adjustment formula on your own.

Why Additional Testing May Follow an Elevated PSA

A biopsy removes tissue so a pathologist can examine it for cancer. It provides information that blood and urine tests cannot, but it also carries risks, including bleeding, infection and urinary complications.

Additional tests can help determine whether the likelihood of clinically significant cancer justifies a biopsy.

In many biomarker studies, “clinically significant” means Grade Group 2 or higher, generally corresponding to a Gleason score of at least 3+4=7. Grade describes how abnormal the cancer looks under a microscope. It is different from stage, which describes the cancer’s extent.

The American Cancer Society’s 2026 early-detection guidance recommends confirming an elevated screening PSA. For most men with a persistently elevated result, MRI and/or a validated biomarker can help guide the biopsy decision. When suspicion is already high, proceeding directly to biopsy may be appropriate.

How PHI and 4Kscore Differ

PHI and 4Kscore are blood tests that provide information beyond total PSA. Their components and intended uses differ.

Test

What it measures

What the result helps assess

Important limitation

Prostate Health Index, or PHI

Total PSA, free PSA and a PSA form called [-2]proPSA

The likelihood of prostate cancer in an appropriate patient population

It cannot confirm cancer or exclude it with certainty

4Kscore

Four blood markers combined with clinical information

The likelihood of Grade Group 2 or higher cancer on biopsy

Its risk estimate must be interpreted with the rest of the evaluation

Prostate Health Index

PHI combines three measurements into one score. It is intended to improve the distinction between prostate cancer and benign conditions compared with total PSA alone.

The FDA’s PHI approval record describes its use in men age 50 and older with total PSA between 4 and 10 ng/mL and a digital rectal examination that is not suspicious for cancer.

That population matters. Evidence supporting a test in one setting should not automatically be extended to every patient with urinary symptoms or an abnormal examination.

4Kscore

4Kscore combines total PSA, free PSA, intact PSA and human kallikrein 2 with information including age, previous biopsy status and digital rectal examination findings.

The FDA’s 4Kscore approval record describes its use to assist biopsy decisions in men age 45 and older with an abnormal age-specific PSA and/or an abnormal examination.

A lower score reduces the estimated likelihood of higher-grade cancer. It does not prove that cancer is absent, establish a diagnosis or independently determine whether follow-up can end. accessdata.fda.gov

What Urine Biomarker Tests Can Tell You

Urine tests analyze genetic material associated with prostate cells. Some require urine collected after a digital rectal examination. Others use urine collected without that examination.

Collection requirements are part of the test’s validated method. Patients should follow the instructions for the specific assay being ordered.

ExoDx Prostate

ExoDx Prostate IntelliScore analyzes RNA within exosomes, small particles released by cells into urine. It does not require a preceding digital rectal examination.

A pooled analysis of three prospective ExoDx studies evaluated its ability to identify Grade Group 2 or higher cancer in men age 50 and older with PSA between 2 and 10 ng/mL who were considering an initial biopsy.

The result helps estimate the likelihood of that biopsy finding. It does not show where a tumor is located or whether cancer has spread.

SelectMDx

SelectMDx measures expression of the HOXC6 and DLX1 genes in urine collected after a digital rectal examination and combines biomarker information with clinical factors.

A prospective multicenter SelectMDx study examined its use alongside MRI in men who had not previously undergone biopsy.

That distinction is important when discussing test performance. Results from an initial-biopsy population do not automatically establish how a test performs after a previous negative biopsy or in a different risk group.

MyProstateScore 2.0

MyProstateScore 2.0, or MPS2, evaluates an 18-gene panel to estimate the likelihood of Grade Group 2 or higher cancer.

Earlier validation used urine collected after a digital rectal examination. A 2025 MPS2 validation study evaluated first-catch urine collected without that examination.

The study supports the use of a non-DRE collection approach, but patients should still follow the instructions for the version their clinician orders. Different collection methods and models should not be treated as interchangeable without supporting evidence. PubMed

PCA3 Requires Current Context

Older articles frequently describe Progensa PCA3 as an FDA-approved option for deciding whether to repeat a biopsy.

However, the FDA’s Progensa PCA3 record lists a withdrawal date of April 12, 2023. Its historical approval should not be presented as proof of current approval or availability.

PCA3 also appears as a component of other assays. A test measuring PCA3 is not necessarily the same product as the former standalone Progensa assay.

Where Prostate MRI Fits

Prostate MRI provides a different kind of information from a biomarker test. It can identify suspicious areas and help guide tissue sampling.

Radiologists commonly use PI-RADS, a standardized scoring system, to describe how suspicious an MRI finding is for clinically significant cancer. A suspicious area may become a target during biopsy.

A reassuring MRI reduces concern in some circumstances, but it does not eliminate the possibility of significant cancer. Whether biopsy remains appropriate depends on the overall risk assessment.

The European Association of Urology’s diagnostic guidance discusses combining MRI findings with factors such as PSA density, examination findings and family history. PSA density relates the PSA level to prostate volume.

When biopsy is deferred, the next step should be explicit. The plan may include repeat PSA testing, clinical reassessment or further imaging, with defined reasons to reconsider biopsy.

When Missed Follow-Up May Support a New York Malpractice Claim

A later prostate cancer diagnosis does not establish malpractice. A claim must connect a departure from accepted medical practice with an injury caused by that departure.

New York courts recognize these separate requirements when evaluating departure from accepted practice and medical causation.

For this topic, a review may examine whether:

  • An abnormal PSA result was received but never reviewed or communicated.

  • Medication-related PSA suppression was overlooked.

  • A recommended urology referral was not completed or appropriately followed up.

  • A low-risk biomarker result was relied on despite other concerning findings.

  • Persistent concern after a negative MRI or biopsy was left without an appropriate reassessment plan.

These are issues for investigation, not automatic findings of fault. Declining to order a particular branded test is not, by itself, proof of negligence.

Discuss a Possible Delay in Prostate Cancer Diagnosis

If you believe an abnormal PSA, concerning test result or recommended referral was not appropriately followed up, a legal review can examine what evaluation was indicated and whether the delay caused additional harm.

Prepare the dates you remember, the providers involved and any results or messages already available. You do not need to assemble a complete medical record before making an inquiry.

Contact Porter Law Group at 833-888-LATE or request a free prostate cancer case evaluation. Continue your medical evaluation and treatment independently of any legal consultation.

This article is for informational and educational purposes only. It is not a substitute for medical advice from a qualified healthcare provider or legal advice based on your specific circumstances.

Attorney Advertising. Reading this article or contacting Porter Law Group does not create an attorney-client relationship.

Should Your Cancer Have Been Found Sooner?

Contact us today for a free consultation.

Frequently Asked Questions

Can prostate cancer occur with a normal PSA?

Yes. A PSA result within a laboratory’s reference range does not completely exclude prostate cancer. PSA must be interpreted alongside examination findings, previous results, medications and other relevant information. Persistent symptoms or an abnormal examination may warrant evaluation even when the PSA is not flagged as high.

Is 4Kscore better than PHI?

Neither test is the best choice for every patient. They use different measurements and have different intended populations. The useful question is whether a particular test adds information that could change your biopsy decision. Your clinician should explain why the selected assay fits your age, PSA level, examination findings and previous biopsy history.

Can a urine test replace a prostate biopsy?

No. Urine biomarkers estimate risk; they do not provide the tissue examination normally needed to confirm prostate cancer and determine its grade. A reassuring result may support deferring biopsy in an appropriate setting, but that decision should account for other findings and include a plan for reassessment.

Does a negative MRI mean I do not need a biopsy?

Not necessarily. A negative MRI lowers concern in some patients but cannot exclude every clinically significant cancer. Your clinician may still recommend biopsy when the overall risk remains concerning. Ask how the MRI fits with your PSA, prostate size, examination findings, family history and previous evaluations.

Is failing to order a newer prostate cancer test malpractice?

Not automatically. Accepted care can involve different reasonable approaches, and every patient does not need every available biomarker. A New York malpractice claim requires evidence that the evaluation departed from accepted practice and caused injury. The review should consider the information and medical guidance available when the care occurred.

Free case evaluation

Talk With a New York Cancer Lawyer

If a delayed diagnosis changed your family's future, Porter Law Group can review what happened and explain your options.